Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

ABSTRACT: We tested the recent advancements in adenine base editing in targeting 3 mitochondrial genes and used AAV delivery to perform editing in mice post-mitotic tissues.

ORGANISM(S): Mus musculus

PROVIDER: GSE276406 | GEO | 2026/09/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mitochondrial DNA base editing in vivo via viral DdCBE delivery to somatic cells

Project description:We show that delivering the mitochondrial base editor DdCBEs via AAV transduction of somatic cells efficiently produces precise base editing of the intended region.

2022-01-19 | GSE184064 | GEO

Bimodal Adenine and Cytosine CRISPR Base Editing on DNA

Project description:Adenine and cytosine base editors (ABEs and CBEs) represent a new genome editing technology that allows the programmable installation of A-to-G or C-to-T alterations on DNA. We engineered Streptococcus pyogenes Cas9-based adenine and cytosine base editor (SpACE) that enables efficient simultaneous introduction of A-to-G and C-to-T substitutions in the same base editing window on DNA.

2020-07-02 | GSE137411 | GEO

In vivo adenine base editing of PCSK9 in mice and macaques reduces LDL-cholesterol levels [amplicon-seq]

Project description:The majority of known pathogenic point mutations in the human genome are C•G to T•A substitutions. Adenine base editors (ABEs), comprised of nuclease-impaired Cas9 fused to adenine deaminases, enable direct repair of these mutations, making them promising tools for precision in vivo genome editing therapies. However, prior to application in patients, thorough safety and efficacy studies in relevant model organisms are needed. Here, we apply adenine base editing in vivo in the liver of mice and cynomolgus macaques to install a splice site mutation in PCSK9 and reduce blood low-density lipoprotein (LDL) levels, a well-known risk factor for cardiovascular disease. Intravenous delivery of ABE-encoding mRNA and a locus-specific single guide (sg)RNA utilizing lipid nanoparticle (LNP) technology induce up to 67% editing in the liver of mice and up to 34% editing in the liver of macaques, leading to a reduction of plasma PCSK9 and LDL levels. We observed rapid clearance of ABE mRNA after LNP-mediated delivery, and neither sgRNA-dependent nor sgRNA-independent off-target mutations are detected in genomic DNA. Together, our findings support safety and feasibility of adenine base editing to treat patients with monogenetic liver diseases.

2021-04-13 | GSE168364 | GEO

In vivo adenine base editing of PCSK9 in mice and macaques reduces LDL-cholesterol levels [RNA-seq]

2021-04-13 | GSE168363 | GEO

Bimodal Adenine and Cytosine CRISPR Base Editing on DNA

Project description:Bimodal Adenine and Cytosine CRISPR Base Editing on DNA

| PRJNA565401 | ENA

Therapeutic base editing alleviates restrictive cardiomyopathy

Project description:Restrictive cardiomyopathy (RCM) is a severe cardiac disorder characterized by impaired ventricular filling and diastolic dysfunction, with mutations in sarcomeric proteins representing major causative factors. Mutations of TNNI3 gene (e.g. p.R192H) constitute major genetic causes of RCM, particularly affecting pediatric patients and being associated with poor prognosis. Here, we demonstrate that adenine base editor (ABE) is able effectively correct RCM-causing mutation and alleviate RCM in a murine model. We first developed a novel murine model harboring the Tnni3R193H mutation that recapitulates the hallmark features of human RCM. Importantly, targeted delivery of ABE via adeno-associated virus (AAV) achieved efficient and precise correction of the Tnni3R193H mutation in adult RCM mice, leading to significant improvement of cardiac functions. Our findings establish base editing as a therapeutic strategy for RCM and highlight its broader potential for treating genetic cardiomyopathies in clinical settings.

2025-04-30 | GSE295799 | GEO

Transcriptomic footprinting following restoration of p53 sequence and function utilising Adenine Base Editing

Project description:The tumor suppressor TP53 is the most frequently mutated gene in human cancer. Here, we utilised a Adenine Base Editing system to efficiently repair the p53-R273H hotspot mutation in four cancer cell lines of different origins followed by transcriptomic analysis at three different timepoints to unveil the molecular network of p53 tumor suppression. Moreover, we were able to repair the p53-R175H hotspot in two cell lines of different origins. Our data demonstrates that recovery of wildtype TP53 leads to restoration of p53 function and suggests a preserved network of p53's tumor-suppressive activities following mutation repair that is irrespective of cell type, mutation profile, and epigenetic cell state. Furthermore, we attempted correcting a nonsense mutation in the tumor suppressor gene SMAD4 in one cell line leading to a progressive depletion of cancer cells, albeit with a milder phenotype compared to the one following TP53 repair. Taken together, our data provide a molecular framework following driver mutations repair, besides providing insights into key players orchestrating transcription leading to cell apoptosis. Our findings demonstrate the utility of this Base Editing system to systematically interrogate the functional consequences of cancer driver mutations and the downstream effects on gene expression.

2025-06-16 | GSE287868 | GEO

Adenine Base Editing <i>In Vivo</i> with a Single Adeno-Associated Virus Vector.

Project description: Not available

| S-EPMC9258002 | biostudies-literature

Targeted exon skipping with AAV-mediated split adenine base editors.

Project description:Targeted exon skipping with AAV-mediated split adenine base editors.

| PRJNA491711 | ENA

Targeted exon skipping with AAV-mediated split adenine base editors.

Project description:Techniques for exclusion of exons from mature transcripts have been applied as gene therapies for treating many different diseases. Since exon skipping has been traditionally accomplished using technologies that have a transient effect, it is particularly important to develop new techniques that enable permanent exon skipping. We have recently demonstrated that this can be accomplished using cytidine base editors for permanently disabling the splice acceptor of target exons. We now demonstrate the application of adenine-deaminase base editors to disrupt the conserved adenosine within splice acceptor sites for programmable exon skipping. We also demonstrate that by altering the amino acid sequence of the linker between the adenosine deaminase domain and the Cas9 nickase or by coupling the adenine base editor with a uracil glycosylase inhibitor, the DNA editing efficiency and exon skipping rates improve significantly. Finally, we developed a split base editor architecture compatible with adeno-associated viral packaging. Collectively, these results represent significant progress towards permanent in vivo exon skipping through base editing and, ultimately, a new modality of gene therapy for the treatment of genetic diseases.

2019-09-12 | GSE120125 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data